DMAA SPAC signs $1B deal to merge with AI/analytics firm Power Analytics Global

Drugs Made In America Acquisition Corp.

Definitive merger agreement with Power Analytics Global (PAGC) at target enterprise value of $1.0B; floor of $300M.
Post-close ownership: ~90% to PAGC shareholders, ~10% to existing DMAA shareholders pre-PIPE dilution.
Minimum cash target at closing of $30M (floor $15M) from trust account and/or PIPE financing.
Merger subject to DMAA shareholder approval, SEC S-4 effectiveness, and Nasdaq listing of surviving entity.
Two amendments on April 30, 2026 corrected governing law to Delaware and completed notice address provisions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Drugs Made In America Acquisition Corp. amended Amendment No. 1 to the Merger Agreement with Power Analytics Global Corp valued at revised governing law and jurisdiction provisions, clarified termination provisions, revised notice (effective 2026-04-30).

Action: amendment
Agreement: merger
Counterparty: Power Analytics Global Corp
Value: revised governing law and jurisdiction provisions, clarified termination provisions, revised notice
Effective: 2026-04-30

Exact text from the filing

On April 30, 2026, DMAA and PAGC entered into Amendment No. 1 to the Merger Agreement (“Amendment No. 1”) for the purpose of correcting certain inconsistencies and incomplete items in the Merger Agreement prior to public disclosure.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

Drugs Made In America Acquisition Corp. amended Amendment No. 2 to the Merger Agreement with Power Analytics Global Corp valued at completed notice address provisions including street addresses and email addresses (effective 2026-04-30).

Action: amendment
Agreement: merger
Counterparty: Power Analytics Global Corp
Value: completed notice address provisions including street addresses and email addresses
Effective: 2026-04-30

Exact text from the filing

Also on April 30, 2026, DMAA and PAGC entered into Amendment No. 2 to the Merger Agreement (“Amendment No. 2,” and together with Amendment No. 1, the “Amendments”) for the purpose of completing the notice address provisions set forth in Section 11.1, including the parties’ respective street addresses and email addresses.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Drugs Made In America Acquisition Corp. entered into Definitive Merger Agreement with Power Analytics Global Corp valued at target enterprise valuation of $1.0 billion, Floor Valuation of $300 million, post-closing ownership (effective 2026-04-29).

Action: entry
Agreement: merger
Counterparty: Power Analytics Global Corp
Value: target enterprise valuation of $1.0 billion, Floor Valuation of $300 million, post-closing ownership
Effective: 2026-04-29

Exact text from the filing

On April 29, 2026, Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company” or “DMAA”), entered into a Definitive Merger Agreement (the “Merger Agreement”) with Power Analytics Global Corp, a Delaware corporation engaged in the business of artificial intelligence, advanced analytics and quantum-resistant security solutions (“PAGC”).

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

Drugs Made In America Acquisition Corp. filing history →

Source: SEC EDGAR

accession 0001213900-26-052324

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.